Introduction

Solid tumors represent a diverse group of cancers affecting various organs including stomach, colorectal, pancreatic, ovarian, and others. Each year, millions of people worldwide are diagnosed with solid tumors, making them a significant global health challenge. For patients with advanced solid tumors, access to appropriate treatment options can substantially impact survival and quality of life.

What is a Named Patient Program (NPP)?

A Named Patient Program is a regulated pathway that allows patients with serious or life-threatening conditions to access medications that may not yet be approved for general use in India. In India, NPP operations are governed by the Central Drugs Standard Control Organization (CDSCO) under the Drugs & Cosmetics Rules, 1945.

This program bridges the gap between patients who have exhausted standard treatment options and potentially beneficial medications available internationally, while maintaining strict safety standards.

How Does NPP Work?

Understanding Solid Tumors

Solid tumors differ from blood cancers, arising in specific organs. The treatment landscape varies considerably depending on:

• Cancer origin: Which organ or tissue the cancer started in (stomach, colon, pancreas, ovary, etc.)
• Stage: How far the cancer has spread
• Molecular characteristics:Genetic mutations or protein expression patterns
• Overall health: Patient’s ability to tolerate systemic treatment

This comprehensive assessment guides treatment recommendations.

Eligibility for NPP Access

To qualify for NPP, solid tumor patients typically must meet these criteria:

• Advanced or metastatic disease requiring urgent systemic intervention
• Exhaustion of suitable Indian-approved alternatives or inadequate response to standard treatments
• Medical evidence supporting potential benefit from the requested medication and it is approved in any other country especially USFDA or EMA
• Clear clinical justification by their treating physician
• Informed consent after understanding potential risks and benefits

Available Solid Tumor Treatment Options

Several systemic therapy approaches are used to treat advanced solid tumors:

BRAF-Mutant Solid Tumors

For patients with BRAF V600 mutations (found in various solid tumors including melanoma, colorectal cancer, and others):

• Zelboraf (vemurafenib) – specifically designed for BRAF V600-mutated cancers

MEK Inhibitors

For specific solid tumors with MAPK pathway alterations:

• Available internationally for combination approaches with BRAF or other targeted therapies

Targeted Therapies for Specific Mutations

Advanced genetic testing now identifies actionable mutations in solid tumors:

• Precision medicine approaches targeting specific genetic features
• Therapies addressing ALK, ROS1, NTRK, MET, and other molecular alterations

Immunotherapy Approaches

Checkpoint inhibitors activate the immune system against solid tumor cancer cells:

• Effective for tumors with specific characteristics like high microsatellite instability
• Often combined with traditional chemotherapy for enhanced benefit

Antibody-Drug Conjugates (ADCs)

Novel agents combining targeted antibodies with chemotherapy:

• Deliver treatment specifically to cancer cells while minimizing effects on healthy tissue

Combination Therapies

Modern treatment often combines:

• Targeted therapy + immunotherapy
• Chemotherapy + immunotherapy
• Sequential approaches as disease adapts to initial treatment

Comprehensive Molecular Testing for Solid Tumors

Before targeted therapy can be recommended, comprehensive testing of your cancer cells is essential:

• Gene mutation testing: Identifies actionable alterations (BRAF, KRAS, TP53, BRCA, others)
• Gene amplification testing: Detects duplications predicting treatment response
• Microsatellite instability (MSI) testing: Identifies immunotherapy candidates
• Tumor mutational burden (TMB) testing: Predicts checkpoint inhibitor benefit
• PD-L1 expression testing: Identifies immunotherapy-responsive tumors

These tests guide your doctor’s treatment recommendations and help identify NPP-eligible options.

The Role of Advocates Like MitoGENE

Organizations like MitoGENE facilitate the NPP process by:

• Educating patients and physicians about NPP and eligibility
• Facilitating patients to get 12 B import permit for personal use from CDSCO
• Connecting patients with legitimate international medicine sources
• Ensuring regulatory compliance
• Providing documentation support for NPP applications
• Coordinating logistics for legal importation and delivery

By working with MitoGENE, patients access expertise and connections necessary to navigate NPP successfully.

*Please Note: All clinical decisions—including whether a therapy is suitable—are made solely by the treating physician. MitoGENE does not influence prescribing decisions or the medical judgment of physicians.*

Conclusion

The Named Patient Program provides an important mechanism for patients with advanced solid tumors to access innovative medications not yet widely available in India, while maintaining rigorous safety standards.

For patients with advanced disease who have exhausted standard Indian treatment options, NPP may provide access to promising therapies available internationally.

This pathway recognizes that fixed approval timelines can disadvantage patients with urgent medical needs. However, NPP is not a replacement for standard treatment—it is a carefully controlled access mechanism for specific patients in genuine medical need.

Key Reminder: This information is educational. Patients considering NPP should engage in detailed discussions with their treating oncologists regarding whether NPP is appropriate for their individual circumstances, what realistic expectations are, and what potential risks exist for any treatment being considered.

For personalized information about treatment options and whether NPP might be suitable for your specific solid tumor situation, consult with your oncologist or an experienced cancer treatment center.